Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7168
Source ID: NCT01676233
Associated Drug: Insulin Glargine (Hoe901)
Title: Repeated Dose Study With a New Insulin Glargine Formulation and LantusĀ® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG: insulin glargine (HOE901)|DRUG: insulin glargine- new formulation (HOE901)
Outcome Measures: Primary: Change in 24-hour blood glucose profile measured by continuous glucose monitoring, Baseline, Day 28, Day 56 | Secondary: Hypoglycemia categorized by the definition of American Diabetes Association, Up to Day 56|Change in fasting plasma glucose from baseline to each treatment end by treatment, Baseline, Day 28, Day 56|Change in self monitoring plasma glucose profile from baseline to each treatment end by treatment, Baseline, Day 28, Day 56|Change in HbA1c from baseline to each treatment end by treatment, Baseline, Day 28, Day 56
Sponsor/Collaborators: Sponsor: Sanofi
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 20
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2012-09
Completion Date: 2013-08
Results First Posted:
Last Update Posted: 2013-08-19
Locations: Investigational Site Number 392001, Kumamoto-Shi, Japan
URL: https://clinicaltrials.gov/show/NCT01676233